FT  04 AUG 94 / International Company News: RPR seeking approval for
anti-cancer drug
Rhone-Poulenc Rorer, the US pharmaceuticals arm of Rhone-Poulenc of France,
yesterday announced it had submitted licence applications in the US, Canada
and Europe, for Taxotere, its anti-cancer drug.
The submissions represent the first global application since RPR was
acquired by Rhone-Poulenc in 1990. The submissions are for use in breast
cancer and lung cancer.
